Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 14, 2026 17:37 ET | Source: Robbins LLP

IMMP Class Action Notice: Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the Immutep Limited Class Action Lawsuit

Robbins LLP is Investigating Allegations that Immutep Limited (IMMP) Misled Investors Regarding the Viability and Efficacy of its Drug Candidate
May 08, 2026 17:31 ET | Source: Robbins LLP

IMMP Class Action Reminder - Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the Immutep Limited Class Action Lawsuit

Robbins LLP is Investigating Allegations that Immutep Limited (IMMP) Misled Investors Regarding the Viability and Efficacy of its Drug Candidate
May 08, 2026 15:22 ET | Source: Robbins LLP

RGC Investors Have Rights – If You Lost Money Investing in Regencell Bioscience Holdings Limited Contact Robbins LLP for Information About Recovering Your Losses

Robbins LLP is Investigating Allegations that Regencell Bioscience Holdings Limited (RGC) was Impacted by a Stock Manipulation Scheme
April 21, 2026 14:34 ET | Source: Robbins LLP

Robbins LLP Urges ATRA Stockholders to Contact the Firm for Information About the Class Action Against Atara Biotherapeutics, Inc.

Robbins LLP is Investigating Allegations that Atara Biotherapeutics, Inc. (ATRA) Misled Investors Regarding its Drug Candidate
April 21, 2026 08:30 ET | Source: Oncotelic Therapeutics, Inc.

Oncotelic Therapeutics Inc. (OTCQB: OTLC) Leveraging Expertise amid Evaluation Evolution

NEW YORK, April 21, 2026 (GLOBE NEWSWIRE) -- via BioMedWire — Oncotelic Therapeutics Inc. (OTCQB: OTLC) today announces its placement in an editorial published by BioMedWire (BMW), one of 75+ brands...
March 31, 2026 20:51 ET | Source: Robbins LLP

Did You Lose Money Investing in Atara Biotherapeutics, Inc.? Robbins LLP Encourages Investors with Significant Losses to Contact the Firm About Their Rights Against ATRA

Robbins LLP is Investigating Allegations that Atara Biotherapeutics, Inc. (ATRA) Misled Investors Regarding its Drug Candidate
March 27, 2026 14:23 ET | Source: Robbins LLP

IBRX Stockholder Alert: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Lawsuit Against ImmunityBio, Inc.

Robbins LLP is Investigating Allegations that ImuunityBio, Inc. (IBRX) Misled Investors Regarding its Lead Product Candidate
March 26, 2026 17:28 ET | Source: Robbins LLP

ATRA Class Action Reminder - Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the Atara Biotherapeutics, Inc. Class Action

Robbins LLP is Investigating Allegations that Atara Biotherapeutics, Inc. (ATRA) Misled Investors Regarding its Drug Candidate
February 20, 2026 17:11 ET | Source: Robbins LLP

RGNX Stockholder Alert: Robbins LLP Remind Investors of the Class Action Lawsuit Against REGENXBIO, Inc.

Robbins LLP is Investigating Allegations that REGENXBIO, Inc. (RGNX) Misled Investors Regarding the Viability of its Drug Candidate RGX-111
February 16, 2026 19:42 ET | Source: Robbins LLP

QURE Class Action Notice: Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the uniQure N.V. Class Action

The Allegations: Robbins LLP is Investigating Allegations that uniQure (QURE) Misled Investors Regarding the Likelihood of FDA Approval of its Drug.